One of Ottawa’s most-lauded biotech startups is strengthening its leadership team with several veteran pharmaceutical executives as the company enters “a new phase” of business growth.
Dr. David Stojdl
An Ottawa biotech startup has received a US$41-million injection of venture capital to further develop its groundbreaking treatments that use the body’s own immune system to battle cancer.
